专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20200181706A1 BIOMARKERS FOR ASSESSING THE RESPONSE STATUS FOR TREATMENT OF INFLAMMATORY CONDITION OR DISEASE AFFECTING THE DIGESTIVE TRACT SUCH AS INFLAMMATORY BOWEL DISEASE IN HUMAN PATIENTS 审中-公开
公开(公告)号：US20200181706A1
公开(公告)日：2020-06-11
申请号：US16636162
申请日：2018-08-03
申请人： OSE IMMUNOTHERAPEUTICS , CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
发明人： Nicolas POIRIER , Richard DANGER
IPC分类号： C12Q1/6883 , C07K16/24 , C07K16/28
摘要： The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TNFalpha agents, for treatment with anti-α4β7 agents or with both anti-TNFalpha agent and anti-α4β7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-α4β7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease. The invention describes a method of in vitro assessing whether a treatment with anti-TNFalpha agent or with anti-α4β7 agent may be useful in a human patient suffering from inflammatory condition or disease, in particular when said condition or disease is a chronic and/or relapsing one, particularly a gastrointestinal, more particularly intestinal, inflammatory condition or disease which is eligible for treatment with anti-TNFalpha agent or respectively with anti-α4β7 agent. In a specific embodiment the method is suitable to assess whether such patient would be non-responsive to treatment with such anti-TNFalpha agent or respectively with anti-α4β7 agent and comprising determining a molecular signature in a biological sample previously obtained from said human patient.

2. 发明申请

US20220389104A1 Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent 有权
公开(公告)号：US20220389104A1
公开(公告)日：2022-12-08
申请号：US17334158
申请日：2021-05-28
申请人： OSE IMMUNOTHERAPEUTICS
发明人： Nicolas POIRIER , Irène BACCELLI , Caroline MARY , Sabrina PENGAM
IPC分类号： C07K16/28 , A61P35/02 , A61K31/573
摘要： The invention pertains to the field of immunotherapy. The present invention provides a new use of anti-CD127 agent, in particular anti-CD127 antibodies or related compounds for the treatment and/or the prevention of cancer.
The invention relates to a method for treating a patient having a CD127-positive cancer, in particular a CD127-positive leukemia, by administering to the patient a therapeutic dose of an anti-CD127 agent, the anti-CD127 agent having the capability to enhance the Antibody Dependent Cellular Phagocytosis (ADCP) activity of macrophages targeting CD127-positive cancer cells, and that does not have Antibody Dependent Cytotoxic Activity (ADCC), in particular on immune cells, more particularly on T cells.

3. 发明申请

US20210040206A1 USE OF ANTI-HUMAN SIRPA V1 ANTIBODIES AND METHOD FOR PRODUCING ANTI-SIRPA V1 ANTIBODIES 有权
公开(公告)号：US20210040206A1
公开(公告)日：2021-02-11
申请号：US16979627
申请日：2019-03-13
申请人： OSE IMMUNOTHERAPEUTICS
发明人： Nicolas POIRIER , Vanessa GAUTTIER , Caroline MARY , Sabrina PENGAM , Bernard VANHOVE
IPC分类号： C07K16/28
摘要： The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.

4. 发明申请

US20220332834A2 ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127 有权
公开(公告)号：US20220332834A2
公开(公告)日：2022-10-20
申请号：US17363260
申请日：2021-06-30
申请人： OSE IMMUNOTHERAPEUTICS
发明人： Nicolas POIRIER , Caroline MARY , Bernard VANHOVE , Virginie THEPENIER
IPC分类号： C07K16/28 , C07K16/24
摘要： The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.

5. 发明申请

US20210395376A1 ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127 有权
公开(公告)号：US20210395376A1
公开(公告)日：2021-12-23
申请号：US17363260
申请日：2021-06-30
申请人： OSE IMMUNOTHERAPEUTICS
发明人： Nicolas POIRIER , Caroline MARY , Bernard VANHOVE , Virginie THEPENIER
IPC分类号： C07K16/28 , C07K16/24
摘要： The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.

6. 发明公开

US20230331852A1 ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF 审中-公开
公开(公告)号：US20230331852A1
公开(公告)日：2023-10-19
申请号：US17779428
申请日：2020-12-04
申请人： OSE IMMUNOTHERAPEUTICS , NANTES UNIVERSITE , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
发明人： Elise CHIFFOLEAU , Nicolas POIRIER , Ariane DESSELLE , Virginie THEPENIER , Caroline MARY , Vanessa GAUTTIER , Sabrina PENGAM
IPC分类号： C07K16/28 , A61P35/00
CPC分类号： C07K16/2851 , A61P35/00 , C07K2317/565 , C07K2317/92
摘要： The invention pertains to the field of immunotherapy. The present invention provides new specific anti-CLEC-1A compounds, in particular antibodies. The compounds of the invention are able to specifically binds to CLEC-1A receptor and antagonize the binding of CLEC-1A to its endogenous ligand(s). The use of the compounds of the invention may be useful for treating deleterious conditions.

7. 发明申请

US20190382497A1 Antibodies Directed Against CD127 审中-公开
公开(公告)号：US20190382497A1
公开(公告)日：2019-12-19
申请号：US16532000
申请日：2019-08-05
申请人： OSE IMMUNOTHERAPEUTICS
发明人： Nicolas POIRIER , Caroline MARY , Bernard VANHOVE
IPC分类号： C07K16/28 , G01N33/68
摘要： The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope comprising sequences from the 2b site of CD127, in particular the epitope comprising comprises the human CD127 sequences of domain D1 and of the 2b site of CD127, in particular the epitope comprises at least one sequence from D1 comprising SEQ ID No: 115 (in particular comprising SEQ ID No: 110) and/or SEQ ID No: 111 and/or a sequence from the 2b site comprising the sequence of SEQ ID No: 116 and optionally also comprises SEQ ID No: 117 (in particular comprises SEQ ID No: 111). The antibodies of the invention are suitable for use in order to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymphopoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.

8. 发明申请

US20190309075A1 METHODS FOR PROMOTING T CELLS RESPONSE 审中-公开
公开(公告)号：US20190309075A1
公开(公告)日：2019-10-10
申请号：US16343757
申请日：2017-10-20
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES , OSE IMMUNOTHERAPEUTICS
发明人： Elise CHIFFOLEAU , Géraldine TEPPAZ , Nicolas POIRIER , Bernard VANHOVE , Vanessa GAUTTIER
IPC分类号： C07K16/28 , C07K14/47 , C12N15/115 , A61P35/00
摘要： The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.

9. 发明申请

US20190127477A1 NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS 审中-公开
公开(公告)号：US20190127477A1
公开(公告)日：2019-05-02
申请号：US16093062
申请日：2017-04-14
申请人： OSE IMMUNOTHERAPEUTICS
发明人： Nicolas POIRIER , Caroline MARY , Bernard VANHOVE , Vanessa GAUTTIER , Virginie THEPENIER , Sabrina PENGAM
IPC分类号： C07K16/28 , A61P35/00 , G01N33/68
摘要： The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.

10. 发明申请

US20170129959A1 Antibodies Directed Against CD127 审中-公开
公开(公告)号：US20170129959A1
公开(公告)日：2017-05-11
申请号：US15317355
申请日：2015-06-10
申请人： OSE IMMUNOTHERAPEUTICS
发明人： Nicolas POIRIER , Caroline MARY , Bernard VANHOVE
IPC分类号： C07K16/28 , G01N33/68
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/5041 , G01N33/6854 , G01N2333/5418 , G01N2333/70546 , G01N2333/7155 , G01N2500/00
摘要： The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope comprising sequences from the 2b site of CD127, in particular the epitope comprising comprises the human CD127 sequences of domain D1 and of the 2b site of CD127, in particular the epitope comprises at least one sequence from D1 comprising SEQ ID No: 115 (in particular comprising SEQ ID No: 10) and/or SEQ ID No: 111 and/or a sequence from the 2b site comprising the sequence of SEQ ID No: 116 and optionally also comprises SEQ ID No: 117 (in particular comprises SEQ ID No: 111). The antibodies of the invention are suitable for use in order to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymphopoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式